Cezanne promoted autophagy through PIK3C3 stabilization and PIK3C2A transcription in lung adenocarcinoma

Osimertinib is a promising approved third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) for treating patients with lung adenocarcinoma (LUAD) harboring EGFR-activating mutations, however, almost all patients develop resistance to Osimertinib eventually limiting the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yadong, Li, Jiahao, Zheng, Haotian, Wang, Kai, Ren, Xiaoyang, Wang, Guanghui, Du, Jiajun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439204/
https://www.ncbi.nlm.nih.gov/pubmed/37596251
http://dx.doi.org/10.1038/s41420-023-01599-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439204/
https://www.ncbi.nlm.nih.gov/pubmed/37596251
http://dx.doi.org/10.1038/s41420-023-01599-4

Ejemplares similares